 |
| Stem Cell Therapy Market in Asia - Pacific to 2018 |
The stem cell therapy market in Asia-Pacific is poised to
offer significant contributions in the future, thanks to renewed interest by
the respective governments of India, China, Japan, South Korea and Singapore to
provide cures for a range of diseases, states a new report.
Stem cells are unique body cells that possess the ability
to divide and differentiate into diverse cell types, and can be used to produce
more stem cells. The use of adult stem cells has been successfully employed to
treat bone and blood related disorders such as leukemia, through bone marrow
transplants. Stem cell therapy is used to repair and regenerate the damaged
tissue, though the actual mechanism of action is largely unknown.
The growth in the stem cell therapy market will not only
provide treatment options but will also contribute significantly to the
countries’ Gross Domestic Product (GDP), with the President of South Korea only
last year referring to stem cell research as a “new growth engine” for the
nation’s economy. In order to support the stem cell industry, regulatory
guidelines in Asia-Pacific countries allow stem cell research, and this has led
to its commercialization. India and South Korea are the leaders in the
commercialization of stem cell therapy, with approved products for Acute
Myocardial Infarction (AMI), osteoarthritis and anal fistula in Crohn’s
disease, amongst others. The countries allow the use of human embryonic stem
cells and provide adequate funding support for the research.
Stem cell therapy is an emerging field, and a large amount
of research is currently being carried out by institutions such as hospitals,
universities and medical colleges. According to Research’s analysis of the stem
cell therapy research in Asia-Pacific, 63% of pipeline molecules were being
researched by academia. The emergence of institutional research has boosted
stem cell discoveries, as companies can be put off conducting research due to
uncertain therapeutic outcomes. China and Japan witness only a negligible
industry presence in stem cell research, as academic institutions dominate –
however in contrast, India has the presence of both industry and academia. The
major institutions engaged in stem cell research in India are LV Prasad Eye
Institute (LYPEI) for Limbal Stem Cell Technology (LSCT), and the Post Graduate
Institute of Medical Education and Research (PGIMER) for stem cell therapy for
type 2 diabetes mellitus.
The market is poised for significant growth in the
future, due to the anticipated launch of JCR Pharmaceuticals’ JR-031 in Japan
in 2014, and FCB Pharmicell’s Cerecellgram (CCG) in South Korea in 2015.
Research report therefore predicts that the stem cell therapy market will grow
in value from $545m in 2012 to $972m in 2018, at a Compound Annual Growth Rate
(CAGR) of 10%.
This report provides an in-depth analysis on
stem cell research and development in India, China, Japan, South Korea and
Singapore. Market analysis and forecasts are given for CABG, LSCT, Type 1 DM,
Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also
provides information on trends and pipelines, and covers market drivers and
challenges for the stem cell research market.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.